AB0682 EXPRESSION AND SIGNIFICANCE ANALYSIS OF PEROXIREDOXIN 6 IN RHEUMATOID ARTHRITIS PATIENTS
Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pat...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 83; no. Suppl 1; p. 1628 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
BMJ Publishing Group Ltd and European League Against Rheumatism
01.06.2024
Elsevier B.V Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pathogenesis of RA. Peroxiredoxin 6(Prdx6), a newly discovered member of the peroxidase family, has both glutathione-peroxidase activity and phospholipase A2 activity, and plays an important role in anti-oxidative stress damage and apoptosis regulation. Current researchs on Prdx6 to attenuate oxidative damage has focused on the respiratory, nervous, and digestive systems, with fewer studies on rheumatic and immune systems.Objectives:The purpose of this study was to investigate the expression of Prdx6 in serum of patients with RA and its correlation with disease activity,inflammatory indicators.Methods:57 patients diagnosed with RA and 31 demographically matched healthy control subjects participated in this study.Clinical datas of enrolled RA patients were collected,including disease activity, inflammatory markers, cytokines, and immune markers. Disease activity indices of patients were calculated with Disease Activity Score-28 Index(DAS-28). The levels of Prdx6 in serum samples were measured by Enzyme-Linked Immunosorbent Assay(ELISA). RA patients were categorized into two groups according to disease activity: low-moderate disease activity and high disease activity. The results obtained were analyzed by multivariate statistical analysis.Results:The serum Prdx6 level of RA patients was significantly decreased compared with that of healthy control group(1.307±0.500ng/ml vs 2.051±0.775ng/ml, p<0.05). Additionally,erythrocyte sedimentation rate(ESR) was faster in the group with high disease activity than the group with low-moderate disease activity(p<0.05). However,there were no statistically significant differences in immunoglobulin,complement,rheumatoid factor(RF),C-reactive proteinand(CRP),anti-cyclic citrullinated peptide(CCP) antibodies between patients with different levels of disease activity. Meanwhile,disease activity and ESR were negatively correlated with prdx6 level(rs -0.284,p<0.05;rs -0.332,p<0.05). But there was no correlation between prdx6 levels and CRP, IL-6, TNF-ɑ, immunoglobulin, RF,anti-CCP antibodies.Conclusion:Our study shows that prdx6 expression is decreased in RA patients and it was negatively correlated with disease activity and ESR,but its specific pathway of action is unclear and needs further study. Exogenous supplement of Prdx6 may alleviate the oxidative stress damage in RA patients and may be one of the treatment methods for RA.REFERENCES:[1] Wu H, Wu R, Liu T, et al. Peroxiredoxin 6 alleviates high glucose-induced inflammation and apoptosis in HK-2 cells by inhibiting TLR4/NF-κB signaling[J]. Ann Transl Med. 2023;11(2):41.[2] Chen X, Tzekov R, Su M, et al. Hydrogen peroxide-induced oxidative damage and protective role of peroxiredoxin 6 protein via EGFR/ERK signaling pathway in RPE cells[J]. Front Aging Neurosci. 2023;15:1169211.[3] Quiñonez-Flores CM, González-Chávez SA, Del Río Nájera D,et al. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. Biomed Res Int. 2016;2016:6097417.[4] Zamudio-Cuevas Y, Martínez-Flores K, Martínez-Nava GA,et al. Rheumatoid Arthritis and Oxidative Stress[J]. Cell Mol Biol (Noisy-le-grand). 2022;68(6):174-184.Acknowledgements:NIL.Disclosure of Interests:None declared. |
---|---|
AbstractList | Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pathogenesis of RA. Peroxiredoxin 6(Prdx6), a newly discovered member of the peroxidase family, has both glutathione-peroxidase activity and phospholipase A2 activity, and plays an important role in anti-oxidative stress damage and apoptosis regulation. Current researchs on Prdx6 to attenuate oxidative damage has focused on the respiratory, nervous, and digestive systems, with fewer studies on rheumatic and immune systems.Objectives:The purpose of this study was to investigate the expression of Prdx6 in serum of patients with RA and its correlation with disease activity,inflammatory indicators.Methods:57 patients diagnosed with RA and 31 demographically matched healthy control subjects participated in this study.Clinical datas of enrolled RA patients were collected,including disease activity, inflammatory markers, cytokines, and immune markers. Disease activity indices of patients were calculated with Disease Activity Score-28 Index(DAS-28). The levels of Prdx6 in serum samples were measured by Enzyme-Linked Immunosorbent Assay(ELISA). RA patients were categorized into two groups according to disease activity: low-moderate disease activity and high disease activity. The results obtained were analyzed by multivariate statistical analysis.Results:The serum Prdx6 level of RA patients was significantly decreased compared with that of healthy control group(1.307±0.500ng/ml vs 2.051±0.775ng/ml, p<0.05). Additionally,erythrocyte sedimentation rate(ESR) was faster in the group with high disease activity than the group with low-moderate disease activity(p<0.05). However,there were no statistically significant differences in immunoglobulin,complement,rheumatoid factor(RF),C-reactive proteinand(CRP),anti-cyclic citrullinated peptide(CCP) antibodies between patients with different levels of disease activity. Meanwhile,disease activity and ESR were negatively correlated with prdx6 level(rs -0.284,p<0.05;rs -0.332,p<0.05). But there was no correlation between prdx6 levels and CRP, IL-6, TNF-ɑ, immunoglobulin, RF,anti-CCP antibodies.Conclusion:Our study shows that prdx6 expression is decreased in RA patients and it was negatively correlated with disease activity and ESR,but its specific pathway of action is unclear and needs further study. Exogenous supplement of Prdx6 may alleviate the oxidative stress damage in RA patients and may be one of the treatment methods for RA.REFERENCES:[1] Wu H, Wu R, Liu T, et al. Peroxiredoxin 6 alleviates high glucose-induced inflammation and apoptosis in HK-2 cells by inhibiting TLR4/NF-κB signaling[J]. Ann Transl Med. 2023;11(2):41.[2] Chen X, Tzekov R, Su M, et al. Hydrogen peroxide-induced oxidative damage and protective role of peroxiredoxin 6 protein via EGFR/ERK signaling pathway in RPE cells[J]. Front Aging Neurosci. 2023;15:1169211.[3] Quiñonez-Flores CM, González-Chávez SA, Del Río Nájera D,et al. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. Biomed Res Int. 2016;2016:6097417.[4] Zamudio-Cuevas Y, Martínez-Flores K, Martínez-Nava GA,et al. Rheumatoid Arthritis and Oxidative Stress[J]. Cell Mol Biol (Noisy-le-grand). 2022;68(6):174-184.Acknowledgements:NIL.Disclosure of Interests:None declared. Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pathogenesis of RA. Peroxiredoxin 6(Prdx6), a newly discovered member of the peroxidase family, has both glutathione-peroxidase activity and phospholipase A2 activity, and plays an important role in anti-oxidative stress damage and apoptosis regulation. Current researchs on Prdx6 to attenuate oxidative damage has focused on the respiratory, nervous, and digestive systems, with fewer studies on rheumatic and immune systems. The purpose of this study was to investigate the expression of Prdx6 in serum of patients with RA and its correlation with disease activity,inflammatory indicators. 57 patients diagnosed with RA and 31 demographically matched healthy control subjects participated in this study.Clinical datas of enrolled RA patients were collected,including disease activity, inflammatory markers, cytokines, and immune markers. Disease activity indices of patients were calculated with Disease Activity Score-28 Index(DAS-28). The levels of Prdx6 in serum samples were measured by Enzyme-Linked Immunosorbent Assay(ELISA). RA patients were categorized into two groups according to disease activity: low-moderate disease activity and high disease activity. The results obtained were analyzed by multivariate statistical analysis. The serum Prdx6 level of RA patients was significantly decreased compared with that of healthy control group(1.307±0.500ng/ml vs 2.051±0.775ng/ml, p<0.05). Additionally,erythrocyte sedimentation rate(ESR) was faster in the group with high disease activity than the group with low-moderate disease activity(p<0.05). However,there were no statistically significant differences in immunoglobulin,complement,rheumatoid factor(RF),C-reactive proteinand(CRP),anti-cyclic citrullinated peptide(CCP) antibodies between patients with different levels of disease activity. Meanwhile,disease activity and ESR were negatively correlated with prdx6 level(rs -0.284,p<0.05;rs -0.332,p<0.05). But there was no correlation between prdx6 levels and CRP, IL-6, TNF-ɑ, immunoglobulin, RF,anti-CCP antibodies. Our study shows that prdx6 expression is decreased in RA patients and it was negatively correlated with disease activity and ESR,but its specific pathway of action is unclear and needs further study. Exogenous supplement of Prdx6 may alleviate the oxidative stress damage in RA patients and may be one of the treatment methods for RA. [1] Wu H, Wu R, Liu T, et al. Peroxiredoxin 6 alleviates high glucose-induced inflammation and apoptosis in HK-2 cells by inhibiting TLR4/NF-κB signaling[J]. Ann Transl Med. 2023;11(2):41. [2] Chen X, Tzekov R, Su M, et al. Hydrogen peroxide-induced oxidative damage and protective role of peroxiredoxin 6 protein via EGFR/ERK signaling pathway in RPE cells[J]. Front Aging Neurosci. 2023;15:1169211. [3] Quiñonez-Flores CM, González-Chávez SA, Del Río Nájera D,et al. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. Biomed Res Int. 2016;2016:6097417. [4] Zamudio-Cuevas Y, Martínez-Flores K, Martínez-Nava GA,et al. Rheumatoid Arthritis and Oxidative Stress[J]. Cell Mol Biol (Noisy-le-grand). 2022;68(6):174-184. NIL. None declared. |
Author | Long, L. Wang, R. Zhong, X. Guo, H. Zheng, X. Zheng, Y. Zhang, W. |
Author_xml | – sequence: 1 givenname: H. surname: Guo fullname: Guo, H. organization: University of Electronic Science and Technology of China, Chengdu, China – sequence: 2 givenname: X. surname: Zheng fullname: Zheng, X. organization: Sichuan Provincial People’s Hospital, Chengdu, China – sequence: 3 givenname: R. surname: Wang fullname: Wang, R. organization: Sichuan Provincial People’s Hospital, Chengdu, China – sequence: 4 givenname: Y. surname: Zheng fullname: Zheng, Y. organization: Sichuan Provincial People’s Hospital, Chengdu, China – sequence: 5 givenname: W. surname: Zhang fullname: Zhang, W. organization: Sichuan Provincial People’s Hospital, Chengdu, China – sequence: 6 givenname: X. surname: Zhong fullname: Zhong, X. organization: Chongqing General Hospital, Department of Geratology, Chongqing, China – sequence: 7 givenname: L. surname: Long fullname: Long, L. organization: Sichuan Provincial People’s Hospital, Department of Rheumatology, Chengdu, China |
BookMark | eNqNkN9OgzAUxhujifPPO5B4jbbQlhKvcOu2JhMWYMm8aqCUyOJAy2binTe-qE9iJyZ66c1pe_J93-n5nYHjtms1AFcIXiPk05uibc2j3m-rpnc96GFX758Kc-15AT4CI4Qps20Kj8EIQui7OKTBKTjr-419QobYCBTRHaTM-3z_4OtlyrNMJLETxRMnE7NYTMU4isfcNqLFQyYyJ5k6S54ma5Hyia2xQx1b0jlf3Ud5IiZOlObzVORWuoxyweM8uwAndfHU68uf8xyspjwfz91FMrPxC7dEIWRuTSpCFApCRTStIKU4RKr2y7IOUIVCQnSlSVFjVbNQF5jVqLArKOXjsrJ37J-DqyH32XQve93v5Kbbm9aOlD6khFESesyqbgeVMl3fG13LZ9NsC_MmEZQHpvIPU3lgKr-ZygNT6-aDW9tFXhttZK8a3SpdNUarnay65p85wZBTbje_3_yP8wvaEpaW |
ContentType | Journal Article |
Copyright | Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. |
Copyright_xml | – notice: Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. – notice: 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. |
DBID | AAYXX CITATION K9. |
DOI | 10.1136/annrheumdis-2024-eular.2274 |
DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) |
DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
EndPage | 1628 |
ExternalDocumentID | 10_1136_annrheumdis_2024_eular_2274 S000349672417358X annrheumdis |
GroupedDBID | --- .55 .GJ .VT 169 23M 2WC 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAXUO ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACPRK ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FDB FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP 0R~ AAFWJ AALRI PHGZM PJZUB PPXIY PQGLB PUEGO AAYXX CITATION K9. |
ID | FETCH-LOGICAL-b1908-f5d55c179c5e6d066491cf3bbf71d1955ede5af4cf89ea48f1a008cc34bdf1a43 |
ISSN | 0003-4967 |
IngestDate | Fri Jul 25 11:09:14 EDT 2025 Thu Jul 31 00:26:26 EDT 2025 Sat Aug 30 17:13:07 EDT 2025 Thu Apr 24 22:50:08 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Keywords | Biomarkers Cytokines and Chemokines |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b1908-f5d55c179c5e6d066491cf3bbf71d1955ede5af4cf89ea48f1a008cc34bdf1a43 |
Notes | EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
PQID | 3065865928 |
PQPubID | 2041045 |
PageCount | 1 |
ParticipantIDs | proquest_journals_3065865928 crossref_primary_10_1136_annrheumdis_2024_eular_2274 elsevier_sciencedirect_doi_10_1136_annrheumdis_2024_eular_2274 bmj_journals_10_1136_annrheumdis_2024_eular_2274 |
PublicationCentury | 2000 |
PublicationDate | 2024-June June 2024 2024-06-00 20240601 |
PublicationDateYYYYMMDD | 2024-06-01 |
PublicationDate_xml | – month: 06 year: 2024 text: 2024-June |
PublicationDecade | 2020 |
PublicationPlace | Kidlington |
PublicationPlace_xml | – name: Kidlington |
PublicationTitle | Annals of the rheumatic diseases |
PublicationTitleAbbrev | Ann Rheum Dis |
PublicationYear | 2024 |
Publisher | BMJ Publishing Group Ltd and European League Against Rheumatism Elsevier B.V Elsevier Limited |
Publisher_xml | – name: BMJ Publishing Group Ltd and European League Against Rheumatism – name: Elsevier B.V – name: Elsevier Limited |
SSID | ssj0000818 |
Score | 2.4464602 |
Snippet | Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the... Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the... |
SourceID | proquest crossref elsevier bmj |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1628 |
SubjectTerms | Apoptosis Autoimmune diseases Biomarkers Citrulline Cytokines and Chemokines Enzyme-linked immunosorbent assay Erythrocyte sedimentation rate Glutathione Hydrogen peroxide Immunoglobulins NF-κB protein Oxidative stress Pathogenesis Patients Peroxiredoxin Phospholipase A2 Rheumatoid arthritis Rheumatoid factor Scientific Abstracts Signal transduction Statistical analysis TLR4 protein Toll-like receptors |
Title | AB0682 EXPRESSION AND SIGNIFICANCE ANALYSIS OF PEROXIREDOXIN 6 IN RHEUMATOID ARTHRITIS PATIENTS |
URI | https://ard.bmj.com/content/83/Suppl_1/1628.1.full https://dx.doi.org/10.1136/annrheumdis-2024-eular.2274 https://www.proquest.com/docview/3065865928 |
Volume | 83 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgkyZeEFcxGJMleKtSkthOnRekbEuXIJpWaSqypyh2HCEkCoL2hV_PsXPrNkBlL1ZkpaenPp_tz-65IPSWV5UA1sGsuqbMory2LaARxLIVp4KUrqw8He88S7xoRT_kLB9cgkx0yUaM5a8_xpXcxarQB3bVUbL_YdleKHTAM9gXWrAwtHvZODizPe6OwtyMoy6fo5NFLePLJJ7qUo7nIXQEH6-WsalQvgjTeR6n4QW0ycgbQZNG4WoWZPP4YgTMNkrjDF5dBFkcJtlyl7gOiZaNT-JntW1yvbZ_8PTM_HJr7l6j8XAjrZrlJO-7PrV31Ontl67Gu9cQLh3cpfqllVjUb2prdEsrJztro-M1YeC3F23SZis2yoPelvkCpf1wx67bVPG5nir7xhbWOxaaIw0xYdadsEILK4ywQgu7jw5dOFLoaheTfDLs2tzhXXVF_TOO0JtWt3f_0AwYifj65W-c5sbubihL9gg9bM8aOGiA8xjdU-sn6GjWelM8RUWDHzzgBwN-8C5-cIcfPJ_ia_jBHoZmwA_u8YM7_DxDq2mYnUdWW3DDEsALuVWzijEJS7RkyquAjFLfkTURop44leMzpirFyprKmvuqhIntlDBuUhIqKnim5Dk6WH9bqxcI20xQoQOzS5cA5SnhIOdLRYUnSWlXLjlGNgxc0U6mn8UehjtGtBvl4nuTimW_j73vLFK0rLJhiwXgbz8BJ50dB32Jpu7aJYG_vJtar9CDYRqdoIPNj616Dfx2I04NME_R4VmYLNLf0BmZvA |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AB0682+EXPRESSION+AND+SIGNIFICANCE+ANALYSIS+OF+PEROXIREDOXIN+6+IN+RHEUMATOID+ARTHRITIS+PATIENTS&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Guo%2C+H.&rft.au=Zheng%2C+X.&rft.au=Wang%2C+R.&rft.au=Zheng%2C+Y.&rft.date=2024-06-01&rft.issn=0003-4967&rft.volume=83&rft.spage=1628&rft_id=info:doi/10.1136%2Fannrheumdis-2024-eular.2274&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_annrheumdis_2024_eular_2274 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |